Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers by Lothar Häberle, Ramona Erber, Paul Gass, Alexander Hein, Melitta Niklos, Bernhard Volz, Carolin C. Hack, Rüdiger Schulz-Wendtland, Hanna Huebner, Chloë Goossens, Matthias Christgen, Thilo Dörk, Tjoung-Won Park-Simon, Andreas Schneeweiss, Michael Untch, Valentina Nekljudova, Sibylle Loibl, Arndt Hartmann, Matthias W. Beckmann, Peter A. Fasching

Get full text

Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAP... by Darren Korbie, Clare Stirzaker, Oleg Gluz, Christine zu Eulenburg, Ulrike Nitz, Matthias Christgen, Sherko Kuemmel, Eva-Maria Grischke, Helmut Forstbauer, Michael Braun, Mathias Warm, John Hackmann, Christoph Uleer, Bahriye Aktas, Claudia Schumacher, Rachel Wuerstlein, Enrico Pelz, Hans Heinrich Kreipe, Susan J. Clark, Matt Trau, Monika Graeser, Nadia Harbeck

Get full text

HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN by Gilda Schmidt, Oleg Gluz, Matthias Christgen, Mattea Reinisch, Sherko Kümmel, Ulrike Nitz, Michael Braun, Bahriye Aktas, Kerstin Lüdtke-Heckenkamp, Helmut Forstbauer, Eva-Maria Grischke, Claudia Schumacher, Rolf Mahlberg, Wolfram Malter, Toralf Reimer, Benno Nuding, Andrea Stefek, Rachel Wuerstlein, Monika Graeser, Katarzyna Jóźwiak, Sandy Burmeister, Christine zu Eulenburg, Michael Lauseker, Cornelia Kolberg-Liedtke, Aleix Prat, Peter Schmid, Rick Baehner, Hans Heinrich Kreipe, Erich-Franz Solomayer, Nadia Harbeck, on behalf of the West German Stud y Group investigators

Get full text